ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Thursday reported a loss of $51.2 million in its fourth quarter.
On a per-share basis, the Rockville, Maryland-based company said it had a loss of $1.01.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.27 per share.
The biotechnology company posted revenue of $21.2 million in the period, falling short of Street forecasts. Five analysts surveyed by Zacks expected $22.9 million.
For the year, the company reported a loss of $227.1 million, or $4.59 per share. Revenue was reported as $83.3 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGNX at https://www.zacks.com/ap/RGNX
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。